Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bristol-Myers Squibb’s Opdivo Shows 5-Year Survival Benefit in Lung Cancer

Bristol-Myers Squibb released pooled efficacy and safety results from the Phase III CheckMate -017 and CheckMate -057 trials in patients with previously treated advanced NSCLC.

Read More »

After Trial Failure, Tonix Sees Glimmer of Hope for Future of PTSD Drug

Shares of Tonix Pharmaceuticals shot up 25 percent in premarket trading after the company announced there may be a future for its late-stage posttraumatic stress disorder treatment Tonmya after a Phase III trial was halted early in July 2018 following a data review showed an inadequate response.

Read More »

Bellerophon Late-Stage PAH Study Fails

Bellerophon Therapeutics’ Phase III pulmonary arterial hypertension drug INOpulse failed to meet endpoints following a pre-specified interim analysis from a Data Monitoring Committee.

Read More »

Lilly-AstraZeneca abandon Alzheimer’s drug trials

Eli Lilly and AstraZeneca discontinued late-stage trials testing their Alzheimer’s treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.

Read More »

Genmab, Johnson & Johnson Halt Lung Cancer Study

Genmab and J&J’s Janssen division pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced or metastatic NSCLC.

Read More »

Protagonist Therapeutics Discontinues Phase IIb Ulcerative Colitis Study

Protagonist Therapeutics Inc. discontinued a Phase IIb study for the experimental ulcerative colitis treatment PTG-100 following a review from an Independent Data Monitoring Committee (DMC).

Read More »

Merck’s Keytruda Wows in Bladder Cancer Trial

Merck & Co. ended a Phase III trial of Keytruda in advanced urothelial cancer because the immuno-oncology drug met its primary endpoint.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom